American Journal of Cardiovascular Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
AbstractType 2 diabetes mellitus (T2DM) is associated with high cardiovascular morbidity and mortality, and cardiovascular diseases are the leading causes of death and disability in people with T2DM. Unfortunately, therapies strictly aimed at glycemic control have poorly contributed to a significant reduction in the risk of cardiovascular events. On the other hand, randomized controlled trials have shown that five glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and one exendin-based GLP-1 RA reduced atherosclerotic cardiovascular events in patients with diabetes at high cardiovascular risk. Furthermore, a meta-analys...
Source: American Journal of Cardiovascular Drugs - December 27, 2021 Category: Cardiology Source Type: research

Correction to: Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 21, 2021 Category: Cardiology Source Type: research

Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 21, 2021 Category: Cardiology Source Type: research

Comparison of Efficacy and Safety of Statin –Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies
ConclusionsStatin –ezetimibe combination therapy enhances levels of LDL-C and other lipids without increasing the risk of adverse events compared with statin monotherapy. The present meta-analysis presents valid evidence for appropriate drug regimens to treat dyslipidemia in patients with diabetes.RegistrationPROSPERO Identifier Number CRD42021244578 (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 20, 2021 Category: Cardiology Source Type: research

Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism
ConclusionOn PS-matched analysis, there was a difference in in-hospital mortality, especially in the rivaroxaban and apixaban group. Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 20, 2021 Category: Cardiology Source Type: research

Correction to: A  Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 11, 2021 Category: Cardiology Source Type: research

Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension
AbstractCardiovascular disease accounts for more than 17 million deaths globally every year, of which complications of hypertension account for 9.4 million deaths worldwide. Early detection and management of hypertension can prevent costly interventions, including dialysis and cardiac surgery. Non-pharmacological approaches for managing hypertension commonly involve lifestyle modification, including exercise and dietary regulations such as reducing salt and fluid intake; however, a majority of patients will eventually require antihypertensive medications. In 2020, the International Society of Hypertension published worldwi...
Source: American Journal of Cardiovascular Drugs - December 8, 2021 Category: Cardiology Source Type: research

Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study
ConclusionTreatment with ivabradine for 6 months effectively reduced HR and improved functional class and QoL in Chinese patients with chronic HF. Treatment was well tolerated.Clinical Trial RegistrationISRCTN11703380; registered on 8 November 2016. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 8, 2021 Category: Cardiology Source Type: research

Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
The article titled “Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction”. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - December 2, 2021 Category: Cardiology Source Type: research

Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
This article discusses the cases, possible pathogenesis of myopericarditis, and treatment of the condition. Most cases were mild and should not yet change vaccine policies, although prospective studies are needed to better assess the risk –benefit ratios in different groups. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - November 24, 2021 Category: Cardiology Source Type: research

SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness
AbstractHeart failure (HF) represents a major global health and economic burden with still unacceptably high morbidity and mortality rates. In recent decades, novel therapeutic opportunities with a significant impact on HF outcomes have been introduced in addition to angiotensin-converting enzyme (ACE) inhibitors, β-blockers, and mineralocorticoid receptor antagonists. These include drugs such as ivabradine, sacubitril–valsartan, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors. The availability of an extremely large pharmacological armamentarium to face this chronic global disease highlights the i mportance of ...
Source: American Journal of Cardiovascular Drugs - November 17, 2021 Category: Cardiology Source Type: research

Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report
This report summarizes presentations from the “one of a kind” Servier-sponsored symposium,Improving the Management of Hypertension: Acting on Key Factors, which was conducted as part of the European Society of Hypertension (ESH)-International Society of Hypertension (ISH) 2021 ON-AIR meeting. The symposium focused on how low awareness, therapeutic inertia, and nonadherence can be addressed by combining the experience of a patient with the expertise of physicians. May Measurement Month, the ongoing global BP measurement program, is raising awareness of hypertension in over 90 countries, and the 2018 European Society of ...
Source: American Journal of Cardiovascular Drugs - November 9, 2021 Category: Cardiology Source Type: research

Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi
AbstractLeft ventricular thrombi form due to the presence of Virchow ’s triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients wit h left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patient...
Source: American Journal of Cardiovascular Drugs - November 5, 2021 Category: Cardiology Source Type: research

Dapagliflozin Versus Sacubitril –Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus
ConclusionsDapagliflozin seems to offer greater value for money than the ARNI for patients with HFrEF and DM. Our results provide support for contemporary guidelines advocating the use of dapagliflozin in these patients. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - October 21, 2021 Category: Cardiology Source Type: research

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
ConclusionIn over one million patients with NVAF, our results suggest differences in anticoagulation treatment persistence across OAC agents, even after accounting for clinical events after OAC initiation. It is important for clinicians and patients to take these differences into consideration, especially as non-persistence to OAC therapy is associated with thromboembolic complications. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - October 21, 2021 Category: Cardiology Source Type: research